TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intradialytic Progressive Resistance Training for Maintenance Haemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic kidney diseases stage five requiring maintenance hemodialysis.~Exclusion Criteria:~* Patients who have been receiving dialysis for less than 3 months;~* Are under the age of 18years;~* Have medical contradictions to participate in the exercise programs;~* Any uncontrolled medical condition which does not allow participation in exercise;~* Have known neuro-muscular disorders;~* Have any other uncontrolled medical condition, including pregnancy;~* Are not independently ambulant for 50 m;~* Have received anabolic intervention, or had catabolic conditions within the last 3 months;~* Have a cardiac pacemaker or other unsuitable implanted device for magnetic resonance;~* Are vulnerable to heat stress;~* Or are unable to give consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic kidney disease progressive resistance training group (Type: EXPERIMENTAL): Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
- Chronic kidney disease sham exercise group (Type: SHAM_COMPARATOR): Lower body stretching exercise using the easiest rehabilitation elastic Theraband
- Healthy controls progressive resistance training group (Type: EXPERIMENTAL): Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
- Healthy controls sham exercise group (Type: SHAM_COMPARATOR): Lower body stretching exercise using the easiest rehabilitation elastic Theraband

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient men and women age 18 and older~* DSM-IV BDD or its delusional variant for at least 6 months~* BDD is the most problematic psychiatric disorder (in the patient's and clinician's opinion) and the primary reason for seeking treatment~* Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale~Exclusion Criteria:~* Current clinically significant suicidality and/or score on the BDI-II suicide item (#9) \> 1~* Any clinical features requiring a higher level of care~* Mental retardation or borderline intellectual functioning (estimated IQ \< 80 on the Wechsler Abbreviated Scale of Intelligence) or dementia, brain damage, or other cognitive impairment that would interfere with ability to engage in CBT~* DSM-IV substance abuse or dependence within the past 3 months; or a positive urine drug screen for any illicit substances of abuse~* Current manic episode~* Psychotic disorder~* Borderline personality disorder~* Body image concerns accounted for by an eating disorder~* Previous treatment with \> 10 sessions of CBT for BDD~* Subjects cannot be receiving any other psychotherapy or begin such treatment during the study~* Patients can be receiving psychotropic medication if they have taken a stable dose for at least two months before the study baseline assessment and the dose remains stable during the study.~* Presence of any behavior (e.g., violence) that would interfere with full cooperation with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive Behavioral Therapy (Type: EXPERIMENTAL): Group receiving Cognitive-Behavioral Therapy
- Supportive Psychotherapy (Type: ACTIVE_COMPARATOR): Group receiving Supportive Psychotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a BMI of 18.0 to 40.0 kg/m2, inclusive~* Agree to use an acceptable method of contraception for the duration of the study~* Have an MDD primary diagnosis~* Have no more than 2 inadequate responses to antidepressant therapy (ADT) in the current Major Depressive Episode (MDE)~* Additional criteria may apply~Exclusion Criteria:~* Have a current primary Axis-I disorder other than MDD~* Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days~* Have received electroconvulsive therapy treatment within the last 2 years or received more than one course of electroconvulsive treatment during their lifetime~* Have attempted suicide within the past 2 years~* Have a positive test for drugs of abuse~* Are pregnant, planning to become pregnant, or breastfeeding~* Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid antagonists (eg, naltrexone, naloxone)~* Have had a significant blood loss or blood donation within 60 days~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- High Dose (Type: EXPERIMENTAL): None
- Low Dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1.DISEASE CHARACTERISTICS:~* Histopathologically confirmed diagnosis of Langerhans cell histiocytosis according to the criteria defined by the Histiocyte Society~* Demonstration of CD1a antigenic determinants on the surface of lesional cells (by immunocytology or immunohistology) or Birbeck granules in lesional cells by electron microscopy~* Considered at risk or low risk according to the following criteria:~  * Multi-system at risk disease, defined as involvement of one or more risk organs (i.e., hematopoietic system, liver, spleen, or lungs)~    1.No single-system lung involvement~ * Multi-system low-risk disease~    1.Multiple organs involved but without involvement of risk organs~ * Single-system disease 1.Multifocal bone disease (i.e., lesions in 2 or more different bones) 2.Localized special site involvement, such as CNS-risk lesions with intracranial soft tissue extension or vertebral lesions with intraspinal soft tissue extension 3.Vault lesions are not regarded as CNS-risk lesions 2.PATIENT CHARACTERISTICS:~    1. Not pregnant or nursing~   2. Negative pregnancy test~   3. Fertile patients must use effective contraception 3.PRIOR CONCURRENT THERAPY:~    <!-- -->~    1. No prior treatment for Langerhans cell histiocytosis~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): methotrexate,1g/m2,iv.d1 cytosine arabinoside,0.1g/m2,iv.,d1-5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Duration Activity and Metabolic Control After Spinal Cord Injury

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Motor complete SCI (AIS A-B)~Exclusion Criteria:~* Pressure ulcers, chronic infection, lower extremity muscle contractures, deep vein thrombosis, bleeding disorder, recent limb fractures, pregnancy, metformin or other medications for diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acute gene regulation: low frequency (Type: EXPERIMENTAL): Adaptations in gene regulation in response to single-session low-frequency exercise.
- Acute gene regulation: high frequency (Type: EXPERIMENTAL): Adaptations in gene regulation in response to single-session high-frequency exercise.
- Training study: low frequency (Type: EXPERIMENTAL): Adaptations in gene regulation, systemic metabolic markers, and patient-report metrics in response to training with low-frequency exercise.
- Training study: high frequency (Type: EXPERIMENTAL): Adaptations in gene regulation in response to training with high-frequency exercise.
- Comparator cohort (Type: NO_INTERVENTION): Participants will undergo selected outcome measures to provide comparison values for Experimental arms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting for large core breast biopsy in the Radiology Department at the Beth Israel Deaconess Medical Center Boston.~Exclusion Criteria:~Patients are excluded if :~* They are unable to give informed consent, or pass screening for impaired mental function or psychosis.~* They are unable to hear or understand English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Self-hypnotic Relaxation (Type: EXPERIMENTAL): A research assistant displayed defined behaviors of empathic attention and read to the patient a self-hypnotic relaxation script. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
- Standard Care (Type: NO_INTERVENTION): Patients received the routine standard treatment which included application of lidocaine as local anesthetic. This is not considered a unique intervention in terms of the trial. Omitting local anesthetic actually would have been an intervention deviating from routine care.
- Empathic Attention (Type: ACTIVE_COMPARATOR): A research assistant displayed defined behaviors of empathic attention. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* history of allergy symptoms during previous birch pollen season~* positive skin prick test to birch pollen extract~Exclusion Criteria:~* pregnancy~* uncontrolled asthma~* other significant clinical conditions or immune disorders~* subjects taking antihistamines or drugs with antihistamine activity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- All subjects (Type: OTHER): placebo histamine T1 T2 T3 T4 T5 T1-T2-T3 T4-T5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients both sexes~* Age between 30 and 60 years~* Mild to moderate physical activity~* Stable body weight for at least 12 weeks prior to the study~* BMI 25.0 - 34.9 kg/m2~* Diabetes mellitus type 2 of recent diagnosis without pharmacological treatment, with one of the following criteria (fasting blood glucose levels \>126 mg/dl; or postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose \>200 mg/dl~* Informed consent signed~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Previous treatment for glucose~* Fasting glucose ≥250 mg/dL~* Known uncontrolled renal, hepatic, heart or thyroid diseased~* Hypersensibility to ingredients of intervention~* Known allergies to bee stings or their derived products~* Triglycerides ≥500 mg/dL~* Total cholesterol ≥240 mg/dL

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Propolis (Type: EXPERIMENTAL): Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
- Metformin (Type: EXPERIMENTAL): Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules, two times per day before break-fast and dinner during 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~adults with neovascular age-related macula degeneration~Exclusion Criteria:~according to SmPC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Patients with neovascular Age-Related Macula Degeneration (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* =/\> 18 years of age~* Prescribed Continuous Venovenous Hemodialysis (CVVHD) as determined by the primary physician~* Prescribed daptomycin as determined by the primary physician~* Informed consent granted~Exclusion Criteria:~* \< 18 years of age~* Allergy to daptomycin~* Patients being primarily treated with daptomycin for diagnosis of osteomyelitis, meningitis, or pneumonia without adequate concomitant use of other more effective antimicrobial agents as daptomycin is not indicated for primary treatment of these types of infections~* Inability to complete 48 hours of Continuous Venovenous Hemodialysis (CVVHD)~* Concurrent use of other extracorporeal therapies such as Extracorporeal Membrane Oxygenation (ECMO) or plasmapheresis and intermittent hemodialysis~* Inability to obtain informed consent~* Pregnant and/or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lymphatic Filariasis (LF) in Ivory Coast

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women and men 18-70 years~* ≥50 MF/mL based on Nuclepore filtration~* Willing to give informed consent~Exclusion Criteria:~* Prior treatment for LF within last 5 years~* Pregnancy (perform pregnancy test)~* Hemoglobin \<7 g/dL~* Permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension~* AST/ALT and creatinine \>1.5 upper limit of normal~* Proteinuria or hematuria \>3+~* Skin snip positivity for O. volvulus MF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Standard Treatment (Type: ACTIVE_COMPARATOR): Albendazole 400 mg + Ivermectin 200 µg/kg body weight administered annually (at 0, 12 and 24 months)
- ALB 400 mg x2 per year (Type: EXPERIMENTAL): Albendazole 400 mg given at 0, 6, 12, 18, 24 and 30 months
- ALB 800 mg x2 per year (Type: EXPERIMENTAL): Albendazole 800 mg given at 0, 6, 12, 18, 24 and 30 months
- ALB 400mg + IVM 200mcg/kg + DEC 6mg/kg (Type: EXPERIMENTAL): Albendazole 400 mg plus Ivermectin 200 µg/kg body weight plus Diethylcarbamazine 6 mg/kg body weight given one time only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female 18 years of age.~* Patient is on a stable daily statin starting dose for the past 4 weeks of either: atorvastatin 10 mg or; simvastatin 20 mg~* lipid values while on statin monotherapy treatment: LDL-C level of \> 2.5 mmol/L to \* 5.0 mmol/L, triglycerides \< 4.0 mmol/L and total cholesterol \< 7.0 mmol/L.~* Patient with established coronary artery disease such as stable angina; history of myocardial infarction; history of percutaneous coronary intervention (PTCA with or without stent placement); coronary stenosis on angiography; history of unstable angina or non-Q wave myocardial infarction; history of coronary artery bypass graft surgery (CABG); positive MIBI scan. Patients have to be in a stable medical condition.~Exclusion Criteria:~* Patients in whom cholesterol lowering medication regime has changed in the previous 4 weeks.~* Patients who have been treated with any other investigational drug within 3 months of Visit 1.~* Patients who are pregnant or lactating.~* Any condition or situation which, in the opinion of the investigator, might pose a risk to the patient or interfere with participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Arm 1: Active comparator
- 2 (Type: EXPERIMENTAL): Arm 2: Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Inadequate glycemic control on diet/exercise therapy and ipragliflozin monotherapy~* HbA1c ≥7.0% and ≤10.0% before study start~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis~* History of any of the following medications: thiazolidinediones (TZD) and/or insulin within 12 weeks prior to study participation, sitagliptin within 8 weeks prior to study participation.~* Currently has a urinary tract infection or genital infection with subjective symptom

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin + Ipragliflozin (Type: EXPERIMENTAL): Sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
- Placebo + Ipragliflozin (Type: ACTIVE_COMPARATOR): Placebo to sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* .Diagnosis of type 2 diabetes mellitus prior to informed consent~* Male and female patients, on diet and exercise regimen, who are pre-treated with one of the following oral antidiabetic drugs: sulfonylurea, glinide, biguanide, Alpha-glucosidase inhibitor (a-GI), dipeptidyl peptidase-IV (DPP-IV) inhibitor or thiazolidinedione~* glycosylated haemoglobin (HbA1c) at Visit 1: \>=7.0 to =\<10.0% (national glycohemoglobin standardization program)~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose level \>240 mg/dL (\>13.3 mmol/L)~* Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent~* Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): BI 10773 low dose tablet once daily
- BI 10773 high dose (Type: EXPERIMENTAL): BI 10773 high dose tablet once daily
- Metformin (Type: ACTIVE_COMPARATOR): Metformin tablets 500-2250 mg a day (twice or three times per day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete